The Zacks Analyst Blog Highlights: Chevron, Pfizer, Boeing, 3M and Citigroup


Shutterstock photo

For Immediate Release

Chicago, IL - June 20, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Chevron (NYSE: CVX - Free Report ), Pfizer (NYSE: PFE - Free Report ), Boeing (NYSE: BA - Free Report ), 3M (NYSE: MMM - Free Report ) and Citigroup (NYSE: C - Free Report ).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .

Here are highlights from Monday's Analyst Blog:

Top Stock Reports for Tuesday: CVX, PFE, BA & More

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Chevron (NYSE: CVX - Free Report ), Pfizer (NYSE: PFE - Free Report ) and Boeing (NYSE: BA - Free Report ). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today's research reports here >>>

Chevron has handily outperformed the Zacks Integrated Oil Industry over the past year (up +5.4% vs. +0.3%), as well as larger rival ExxonMobil which saw its stock go down -8.7% over the same time period. Chevron's gains reflect the momentum generated by better-than-expected earnings in 3 of the last 4 quarters on the back of rebounding commodity prices, lower expenses and improved U.S. refining environment.

Moreover, Chevron's focus on the prolific Permian basin should allay investor fears about production growth trajectory over the next few years. However, with oil testing the psychologically-critical $50 threshold again, the near-to-medium term revenue outlook for Chevron - one of the most oil-weighted majors - remains cloudy.

Chevron is still outspending its cash flow, making it dependent on asset sales. Hence, the Zacks analyst thinks investors should wait for a better entry point before buying shares in America's second largest oil company.

(You can read the full research report on Chevron here >>> ) .

Shares of Pfizer have underperformed the peer group as well as the broader market over the past year (the stock is down -4.3% over the last year vs. a +5.5% increase for the Zacks Large-Cap Pharma industry and the +16.8% gain for the S&P 500 index) on continued drug pricing uncertainty that have refused to go away even after the election. These headwinds notwithstanding, the Zacks analyst is pointing out that Pfizer is strengthening its product portfolio as well as pipeline through acquisitions and licensing deals.

Also, cost-savings and share buybacks should help Pfizer achieve its earnings guidance. New products like Ibrance and contribution from acquisitions are expected to drive revenues. While the Hospira acquisition has significantly expanded Pfizer's sterile injectable and biosimilar capabilities, the Medivation deal has strengthened its cancer franchise by adding Xtandi to its portfolio.

(You can read the full research report on Pfizer here >>> ) .

Boeing 's shares have surged +49.5% over the past one-year, outperforming the Zacks Aerospace & Defense sector, which gained +26.8% during the same time period. The Zacks analyst stresses that rising demand for its commercial airplanes on the back of steady improvement in passenger and freight traffic is the major factor behind the surge in Boeing shares.

These developments reflect the company's latest expansion on the international front, apart from its strong presence in the domestic aviation market. The improving outlook for defense spending under the Trump administration is another long-term positive in the Boeing story.

However, challenges including uncertain fate of high-cost programs, risks related to key project executions, order cancellations as well as stiff competition might have a negative impact on the company. Also deferred production cost for Boeing's 787 Dreamliner remains a major cause of concern for the company.

(You can read the full research report on Boeing here >>> ) .

Other noteworthy reports we are featuring today include 3M (NYSE: MMM - Free Report ) and Citigroup (NYSE: C - Free Report ).

3 Stocks to Ride a 588% Revenue Explosion

At Zacks, we're mostly focused on short-term profit cycles, but the hottest of all technology mega-trends is starting to take hold...

By last year, it was already generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. See Zacks' Top 3 Stocks to Ride This Space >>

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.

Get the full Report on MMM - FREE

Get the full Report on C - FREE

Get the full Report on CVX - FREE

Get the full Report on BA - FREE

Get the full Report on PFE - FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Chevron Corporation (CVX): Free Stock Analysis Report

Pfizer, Inc. (PFE): Free Stock Analysis Report

Boeing Company (The) (BA): Free Stock Analysis Report

3M Company (MMM): Free Stock Analysis Report

Citigroup Inc. (C): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: Investing , Stocks
Referenced Symbols: CVX , PFE , BA , MMM , C


More from Zacks.com

Subscribe






Zacks.com
Contributor:

Zacks.com

Equity Research
Follow on:








Research Brokers before you trade

Want to trade FX?





Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com